Most Read Articles
Jackey Suen, 21 Dec 2016

Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]

Cathy Chow, PhD, 27 Aug 2015

HER2-positive breast cancer tends to be more aggressive, has worse patient prognosis, and responds less to treatment. A two-pronged approach to block the HER pathway via pertuzumab (Perjeta®, Roche), a first-in-class HER dimerization inhibitor, in combination with trastuzumab and chemotherapy, may offer more treatment options for HER2-positive metastatic breast cancer patients as well as those with early breast cancer. 

Saras Ramiya, 25 Oct 2017
The first patient-reported outcomes study on durvalumab treatment after chemoradiation in locally advanced non-small cell lung cancer (NSCLC) shows patients’ quality of life is similar to that of the patients who received placebo.
Pearl Toh, 19 Dec 2016
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), showed significantly greater efficacy than platinum-pemetrexed therapy in advanced non-small cell lung cancer (NSCLC) patients positive for T790M mutation, including those with central nervous system (CNS) metastases, according to data from the AURA3* trial.

Heavy weed smoking may promote testicular cancer

04 Dec 2017

Heavy use of the cannabis sativa may contribute to the development of testicular cancer, a recent study suggests.

The study included 49,343 young men aged 18 to 21 years who underwent conscription assessment for Swedish military service from 1969 to 1970. They completed a nonanonymous questionnaire to provide information regarding drug use. Testicular cancer diagnoses between 1970 and 2011 were identified via the Swedish National Patient Register, the Cancer Register or the Cause of Death Register.

A total of 135 testicular cancer cases were reported during the follow-up, with more than 50 percent occurring between 25 and 40 years of age.

Cox regression models found no evidence of a significant association between lifetime “ever” cannabis use and the subsequent development of testicular cancer (n=45,250; 119 testicular cancer cases; adjusted HR [aHR], 1.42; 95 percent CI, 0.83 to 2.45). Lifetime “ever” use was defined as having used cannabis, regardless of the frequency.

However, when the frequency of usage was analysed, heavy cannabis use (defined as use of >50 times in lifetime) increased the risk of incident testicular cancer by more than twofold (n= 45,250; 119 testicular cancer cases; aHR 2.57; 1.02 to 6.50).

Tobacco use and alcohol consumption were not related to testicular cancer risk.

While unknown, the mechanism by which cannabis promotes the development of testicular cancer may pertain to the active compounds in phytocannabinoids, such as tetrahydrocannabinol and cannabidiol. These compounds have been reported to bind to cannabinoid receptors in many human organs, including the testes.

In light of the present data and available evidence, researchers pointed out that “emerging changes to cannabis drug policy should consider the potential role of cannabis use in the development of testicular cancer.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Jackey Suen, 21 Dec 2016

Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]

Cathy Chow, PhD, 27 Aug 2015

HER2-positive breast cancer tends to be more aggressive, has worse patient prognosis, and responds less to treatment. A two-pronged approach to block the HER pathway via pertuzumab (Perjeta®, Roche), a first-in-class HER dimerization inhibitor, in combination with trastuzumab and chemotherapy, may offer more treatment options for HER2-positive metastatic breast cancer patients as well as those with early breast cancer. 

Saras Ramiya, 25 Oct 2017
The first patient-reported outcomes study on durvalumab treatment after chemoradiation in locally advanced non-small cell lung cancer (NSCLC) shows patients’ quality of life is similar to that of the patients who received placebo.
Pearl Toh, 19 Dec 2016
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), showed significantly greater efficacy than platinum-pemetrexed therapy in advanced non-small cell lung cancer (NSCLC) patients positive for T790M mutation, including those with central nervous system (CNS) metastases, according to data from the AURA3* trial.